Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pirtobrutinib appeared effective among a cohort of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results published in The New England Journal of Medicine.

The FDA today approved acalabrutinib as initial or subsequent therapy for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.